- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04143490
Effects of Exercise in Patients With Ulcerative Colitis
The Effects of Exercise Intensity on Gastrointestinal Function and Inflammatory Markers in Patients With Ulcerative Colitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is limited research on the effect of exercise on patients with Ulcerative Colitis. The aim of this investigation is to study the acute effects of moderate to high intensity exercise on gut function in patients with Ulcerative Colitis and to compare them with individuals of matched age who do not suffer from Inflammatory Bowel Disease.
Patients in remission from disease activity and age and gender matched healthy control participants will be recruited from the general population. Participants will attend the laboratory on two occasions. The first visit will last approximately one hour and will include an exercise test to determine peak oxygen uptake capacity (VO2peak) which is an indicator of cardiorespiratory fitness. The second visit will last for approximately four and a half hours and will consist of a 60 minute continuous cycle on a stationary cycle ergometer at an intensity of 65% VO2peak followed by a recovery period. Gastric emptying rate of a commercially available sports drink will be measured and blood samples will be collected at regular time-points throughout the visit and analysed for concentrations of inflammatory markers and intestinal integrity/function.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Greater Manchester
-
Manchester, Greater Manchester, United Kingdom, M1 5GD
- Manchester Metropolitan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For ulcerative colitis patients;
- Currently in remission of disease (asymptomatic at time of experiment)
- Less than 3 periods of disease activity (periods of symptomatic activity) in the last 12 months
- No history of surgery to alleviate condition severity
- Taking regular standard medication for control of condition
- Adult less than 50 years due to effects of exercise in older age
- Non-smokers
- Regular exercisers (determined via verbal discussion)
For healthy controls;
- No history of disease (as assessed by standard medical screening questionnaire)
- Adult less than 50 years due to effects of exercise in older age
- Non-smokers
- Regular exercisers (determined via verbal discussion)
Exclusion Criteria:
For ulcerative colitis patients;
- Currently in active period of disease (symptomatic at time of experiment)
- More than 3 periods of disease activity (periods of symptomatic activity) in the last 12 months
- History of surgery to alleviate condition severity
- Taking non-standard medication for control of condition
- Adult more than 50 years of age
- Under 18 years of age
- Smokers
- Sedentary or not regularly physically active (determined via verbal discussion)
For healthy controls;
- History of disease (as assessed by standard medical screening questionnaire)
- Adult more than 50 years of age
- Under 18 years of age
- Smokers
- Sedentary or not regularly physically active (determined via verbal discussion)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: UC Patients
Patient group
|
60 minutes of continuous exercise at 65% VO2peak and drink ingestion
|
|
Active Comparator: Healthy controls
Control group
|
60 minutes of continuous exercise at 65% VO2peak and drink ingestion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in inflammatory markers or hormones
Time Frame: 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
|
Circulating concentrations of Interleukin-6, Tumor Necrosis Factor-alpha, C-reactive protein, glucagon like peptide 2
|
6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
|
|
Area under the circulating concentration versus time curve (AUC) of inflammatory markers or hormones
Time Frame: 4.5 hours
|
Responses of Interleukin-6, Tumor Necrosis Factor-alpha, C-reactive protein, glucagon like peptide 2
|
4.5 hours
|
|
Change in intestinal epithelial damage and permeability markers
Time Frame: 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
|
Circulating concentrations of intestinal fatty acid binding protein and claudin-3
|
6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
|
|
Area under the circulating concentration versus time curve (AUC) of intestinal epithelial damage and permeability markers
Time Frame: 4.5 hours
|
Responses of intestinal fatty acid binding protein and claudin-3
|
4.5 hours
|
|
Change in exercise induced endotoxaemia markers
Time Frame: 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
|
Circulating concentrations of plasma lipopolysaccharide
|
6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
|
|
Area under the circulating concentration versus time curve (AUC) of exercise induced endotoxaemia markers
Time Frame: 4.5 hours
|
Response of plasma lipopolysaccharide
|
4.5 hours
|
|
Gastric emptying rate half time and time of maximal emptying rate
Time Frame: 2 hours after ingestion of drink
|
Emptying rate of a commercially available sports drink from the stomach using the 13C breath test method
|
2 hours after ingestion of drink
|
|
Change in ratio of 13C/12C in breath samples
Time Frame: 9 breath samples collected at baseline, then every 15 minutes after ingestion for 2 hours
|
Gastric emptying profile of a commercially available sports drink from the stomach using the 13C breath test method
|
9 breath samples collected at baseline, then every 15 minutes after ingestion for 2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence and severity of gastrointestinal symptoms
Time Frame: Immediately post-exercise bout and 3 hours post exercise.
|
10-point rating scale for gastrointestinal symptoms (Visual Analogue Scale modified).
19 item questionnaire with 5 subcategories (Overall gut discomfort, total gastrointestinal symptoms, upper gastrointestinal symptoms, lower gastrointestinal symptoms and other gastrointestinal symptoms).
Scores for each item ranging from 0 (no symptom) to 10 (extremely severe symptoms causing exercise reduction, stopping, or complete withdrawal).
Higher scores represent higher severity of symptoms.
|
Immediately post-exercise bout and 3 hours post exercise.
|
|
Heart rate response
Time Frame: Every 5 minutes during 60 minute cycle
|
Heart rate telemetry
|
Every 5 minutes during 60 minute cycle
|
|
Disparity of subjective exertion and objective cardiorespiratory parameters
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion.
Higher scores represent higher perceived exertion) and cardiopulmonary exercise testing variables of oxygen uptake, carbon dioxide expiration, ventilatory threshold, volume of air expired, and tidal volume (all parameters measured in L/min).
|
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
|
Disparity of subjective exertion and objective heart rate
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion.
Higher scores represent higher perceived exertion) and heart rate measured by telemetry
|
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
|
Disparity of subjective exertion and breathing frequency
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion.
Higher scores represent higher perceived exertion) and number of breaths per minute
|
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
|
Disparity of subjective exertion and oxygen pulse
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion.
Higher scores represent higher perceived exertion) and oxygen pulse calculated by dividing oxygen uptake by heart rate.
|
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
|
Disparity of subjective exertion and respiratory exchange ratio
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion.
Higher scores represent higher perceived exertion) and respiratory exchange ratio calculated by dividing carbon dioxide production by oxygen uptake.
|
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
|
Disparity of subjective exertion and ventilatory efficiency
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion.
Higher scores represent higher perceived exertion) and minute ventilation/carbon dioxide slope (VE/VCO2 slope).
|
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
|
|
Subjective physical activity levels
Time Frame: Prior to experimental trial
|
International Physical Activity Questionnaire (IPAQ).
Answers to questions (time spent completing different physical activities) converted to Metabolic Equivalent (METs) hours per week.
Minimum value of zero, no limit to maximum.
Higher MET values indicate higher physical activity levels.
|
Prior to experimental trial
|
|
Attitudes and beliefs towards physical activity
Time Frame: Prior to experimental trial
|
Barriers to Physical Activity Questionnaire.
21 item questionnaire, each question rated from 0 (very unlikely) to 3 (very likely).
Each item belongs to one of 7 categories relating to barriers to physical activity.
Score totals greater than 5 indicate the category as being a significant barrier.
|
Prior to experimental trial
|
|
Subjective health related quality of life: RAND 36-Item Short Form Health Survey (SF-36)
Time Frame: Prior to experimental trial
|
RAND 36-Item Short Form Health Survey (SF-36).
36-item questionnaire covering 8 concepts; physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions, plus single item providing an indication of perceived change in health.
Scores ranging from 0 to 100 for each concept with 100 indicating good health and 0 being poor health.
|
Prior to experimental trial
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gethin H Evans, PhD, Manchester Metropolitan University
- Principal Investigator: Adora MW Yau, PhD, Manchester Metropolitan University
- Principal Investigator: John McLaughlin, Prof., University of Manchester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ExerciseUC-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Cook Children's Health Care SystemNot yet recruitingIBD | IBD - Inflammatory Bowel Disease | IBD (Inflammatory Bowel Disease)United States
-
Ningbo Medical Center Lihuili HospitalRecruitingInflammatory Bowel Disease (IBD)China
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingIBD - Inflammatory Bowel DiseaseItaly
-
Chang Kyun LeeChonnam National University Hospital; Kyungpook National University Hospital; Chung-Ang University Hosptial, Chung-Ang University College of Medicine and other collaboratorsRecruitingInflammatory Bowel Disease (IBD)Korea, Republic of
-
Xijing HospitalNot yet recruitingInflammatory Bowel Diseases (IBD)China
-
Assiut UniversityNot yet recruitingInflammatory Bowel Disease (IBD)
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Texas Southwestern Medical CenterEnrolling by invitationInflammatory Bowel Disease | Inflammatory Bowel Disease (IBD)United States
-
University Hospital, GrenobleInstitute for Advanced Biosciences (IAB), GrenobleNot yet recruitingInflammatory Bowel Disease (IBD)France
Clinical Trials on Exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
Bayero University Kano, NigeriaCompletedChronic Low Back PainNigeria
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University College CorkRecruitingDepressive Disorder, MajorIreland
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of
-
Uskudar UniversityCompleted
-
Yuksek Ihtisas UniversityCompletedDementia | Frailty | Cognitive Function | Reaction Time | Aerobic Exercise | Balance ExerciseTurkey